Keywords
brainstem
medulla oblongata
diagnosis
How to Cite
Abstract
This article presents a 33 months old patient, with failure to thrive, alterations in gait and swallow. Brain and spine magnetic resonance showed masses at medulla and pons, venous thrombosis in the left transverse sinus and metastatic masses to spinal cord. Unresectable metastatic brainstem glioma was diagnosed. Oncology started treatment with chemotherapy and radiotherapy having a survival time of more than 3 years.
Lanskowsky P. Central nervous system malignancies. En: Manual of pediatric hematology and oncology. 4th ed. New York: Elsevier; 2005. p. 513-29.
Saran F. Recent advances in paediatric neuro-oncology. Curr Opin Neurol. 2002 Dic;15(6):671-7.
Hargrave D. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg. 2009 Ago;23(4):351-63.
Qaddoumi I, Sultan I, Broniscer A. Pediatric low-grade gliomas and the need for new options for therapy: Why and how? Cancer Biol Ther. 2009 Ene;8(1):4-10.
Massimino M, Spreafico F, Cefalo G et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002 Oct 15;20(20):4209-16.
Kuo DJ, Weiner HL, Wisoff J, Miller DC et al. Temozolomide is active in childhood, progressive, unresectable, lowgrade gliomas. J Pediatr Hematol Oncol. 2003 May;25(5):372-8.
Rutka JT, Kuo JS. Pediatric surgical neuro-oncology: current best care practices and strategies. J Neurooncol. 2004 Ago-Sep;69(1-3):139-50.
Lashford LS, Thiesse P, Jouvet A et al. A United Kingdom Children‘s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. Temozolomide in malignant gliomas of childhood: a United Kingdom Children‘s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002 Dec 15;20(24):4684-91.
National Institute for Health and Clinical Excellence. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) [internet]. London; 2001. Disponible en: http://publications.nice.org.uk/guidance-on-the-use-of-temozolomidefor-the-treatment-of-recurrent-malignant-glioma-brain-cancer-ta23.
Hart MG, Grant R, Garside R y cols. Temozolomide for high grade glioma (review). s. l.: The Cochrane Collaboration; 2010.
Wagner S, Warmuth-Metz M, Emser. A treatment options in childhood pontine gliomas. J Neurooncol. 2006 Sep;79(3):281-7.
Perilongo G. Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood. J Neurooncol. 2005 Dic;75(3):301-7.
Massimino M, Spreafico F, Riva D et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J. Neurooncol. 2010 Oct;100(1):65-71
Akyüz C, Demir HA, Varan A et al. Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center. Childs Nerv Syst. 2011;28(1):111-5.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.